| Symbol | HOWL |
|---|---|
| Name | WEREWOLF THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1030 MASSACHUSETTS AVENUE,SUITE 210, CAMBRIDGE, Massachusetts, 02138, United States |
| Telephone | +1 617 952-0555 |
| Fax | — |
| — | |
| Website | https://www.werewolftx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001785530 |
| Description | Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer. Additional info from NASDAQ: |
(99% Neutral) WEREWOLF THERAPEUTICS, INC. (HOWL) Reports Q3 2026 Financial Results
Read moreWerewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Read moreEVNIN LUKE 🔴 sold 143.2K shares of Werewolf Therapeutics, Inc. (HOWL) at $0.32 Transaction Date: Jul 06, 2026 | Filing ID: 000020
Read more📋 MPM Oncology Innovations Fund, L.P. (Shareholder) plans to sell 21K shares of Werewolf Therapeutics, Inc. (at $0.34 each, total $7K) Filed: Jul 06, 2026 | ID: 047367
Read more📋 MPM Asset Management Investors BV2014 LLC (Shareholder) plans to sell 3K shares of Werewolf Therapeutics, Inc. (at $0.34 each, total $1K) Filed: Jul 06, 2026 | ID: 047366
Read more📋 MPM Asset Management LLC (Shareholder) plans to sell 15K shares of Werewolf Therapeutics, Inc. (at $0.34 each, total $5K) Filed: Jul 06, 2026 | ID: 047365
Read more📋 UBS Oncology Impact Fund, L.P. (Shareholder) plans to sell 80K shares of Werewolf Therapeutics, Inc. (at $0.34 each, total $27K) Filed: Jul 06, 2026 | ID: 047364
Read more📋 MPM BioVentures 2014 (B), L.P. (Shareholder) plans to sell 6K shares of Werewolf Therapeutics, Inc. (at $0.34 each, total $2K) Filed: Jul 06, 2026 | ID: 047362
Read moreNew Form SCHEDULE 13D/A - Werewolf Therapeutics, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001346824-26-000187 <b>Size:</b> 16 KB
Read moreEVNIN LUKE 🔴 sold 157.1K shares of Werewolf Therapeutics, Inc. (HOWL) at $0.30 Transaction Date: Jun 29, 2026 | Filing ID: 000019
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06939283 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Pat… | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2025-05-07 | 2028-08-01 | ClinicalTrials.gov |
| NCT05678998 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lym… | Phase1 | Advanced or Metastatic Solid Tumors | Completed | 2022-12-06 | 2025-02-05 | ClinicalTrials.gov |
| NCT05479812 | Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combinatio… | Phase1 | Metastatic Solid Tumor | Active_Not_Recruiting | 2022-05-20 | 2026-07-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| WTX-330 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | COMPLETED | NCT05678998 |
| pembrolizumab | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05479812 |
| WTX-124 | Other | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05479812 |
| WTX-330 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06939283 |
| WTX-330 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT06939283 |
| pembrolizumab | DRUG | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05479812 |
| WTX-124 | DRUG | Phase PHASE1 | Metastatic Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05479812 |